Literature DB >> 25818627

Actigraphic-measured sleep disturbance predicts increased positive symptoms in adolescents at ultra high-risk for psychosis: A longitudinal study.

Jessica R Lunsford-Avery1, Monique K LeBourgeois2, Tina Gupta3, Vijay A Mittal4.   

Abstract

BACKGROUND: Sleep disturbance is prevalent among patients with psychosis, yet little is known about sleep health during the ultra high-risk (UHR) period. This study used actigraphy to evaluate sleep in healthy control (HC) and UHR adolescents to examine the relationship between sleep disturbance and psychosis symptoms at baseline and 12-month follow-up, as well as comparisons between objective and subjective measurements of sleep functioning in UHR youth.
METHOD: Thirty-six UHR and 31 HC youth participated in a baseline evaluation including 5 nights of actigraphy, subjective measurement of sleep health (Pittsburgh Sleep Quality Index; PSQI), and clinical interviews. Clinical measures were repeated with UHR youth (N=23) at a 12-month follow-up.
RESULTS: The actigraphy data indicated that UHR youth displayed increased wake time after onset (WASO), increased movements during sleep, and decreased efficiency compared to HC, and several markers of sleep disturbance including decreased efficiency, increased WASO, number of awakenings, and increased movements were associated with symptomatology in the UHR group. Interestingly, there were associations between actigraph and self-report indices of sleep duration and efficiency (at the trend level) but not awakenings. Several objective measures of sleep disturbance and one self-reported measure (disrupted continuity) predicted the longitudinal course of symptoms over 12 months in the UHR group.
CONCLUSIONS: Taken together, the results suggest a potential role for sleep problems in the etiology of schizophrenia, and highlight sleep health as a possible target for prevention/intervention efforts. Additionally, actigraphy represents an inexpensive, sensitive measurement providing unique information not captured by self-report, and may be an informative adjunct to UHR assessments.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Actigraphy; Prodromal; Psychosis; Schizophrenia; Sleep disturbance; Ultra high-risk

Mesh:

Year:  2015        PMID: 25818627      PMCID: PMC4409558          DOI: 10.1016/j.schres.2015.03.013

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  37 in total

1.  Differential results between self-report and interview-based ratings of risk symptoms of psychosis.

Authors:  Niklas Granö; Marjaana Karjalainen; Arja Itkonen; Jukka Anto; Virve Edlund; Markus Heinimaa; Mikko Roine
Journal:  Early Interv Psychiatry       Date:  2011-05-05       Impact factor: 2.732

Review 2.  On the interactions of the hypothalamic-pituitary-adrenal (HPA) axis and sleep: normal HPA axis activity and circadian rhythm, exemplary sleep disorders.

Authors:  Theresa M Buckley; Alan F Schatzberg
Journal:  J Clin Endocrinol Metab       Date:  2005-02-22       Impact factor: 5.958

3.  Direct comparison of two new actigraphs and polysomnography in children and adolescents.

Authors:  Lisa J Meltzer; Colleen M Walsh; Joel Traylor; Anna M L Westin
Journal:  Sleep       Date:  2012-01-01       Impact factor: 5.849

4.  Activity-based sleep-wake identification: an empirical test of methodological issues.

Authors:  A Sadeh; K M Sharkey; M A Carskadon
Journal:  Sleep       Date:  1994-04       Impact factor: 5.849

5.  Axis-I disorders and vulnerability to psychosis.

Authors:  Tanja Svirskis; Jyrki Korkeila; Markus Heinimaa; Jukka Huttunen; Tuula Ilonen; Terja Ristkari; Thomas McGlashan; Raimo K R Salokangas
Journal:  Schizophr Res       Date:  2004-12-02       Impact factor: 4.939

Review 6.  Sleep disturbance in schizophrenia.

Authors:  Jaime M Monti; Daniel Monti
Journal:  Int Rev Psychiatry       Date:  2005-08

7.  Axis I diagnoses and transition to psychosis in clinical high-risk patients EPOS project: prospective follow-up of 245 clinical high-risk outpatients in four countries.

Authors:  Raimo K R Salokangas; Stephan Ruhrmann; Heinrich Graf von Reventlow; Markus Heinimaa; Tanja Svirskis; Tiina From; Sinikka Luutonen; Georg Juckel; Don Linszen; Peter Dingemans; Max Birchwood; Paul Patterson; Frauke Schultze-Lutter; Joachim Klosterkötter
Journal:  Schizophr Res       Date:  2012-03-31       Impact factor: 4.939

8.  Sleep impairment, mood symptoms, and psychosocial functioning in adolescent bipolar disorder.

Authors:  Jessica R Lunsford-Avery; Charles M Judd; David A Axelson; David J Miklowitz
Journal:  Psychiatry Res       Date:  2012-08-09       Impact factor: 3.222

9.  Perceived quality of life in schizophrenia: relationships to sleep quality.

Authors:  Michael Ritsner; Rena Kurs; Alexander Ponizovsky; Jack Hadjez
Journal:  Qual Life Res       Date:  2004-05       Impact factor: 4.147

10.  Sleep and circadian rhythm disruption in schizophrenia.

Authors:  Katharina Wulff; Derk-Jan Dijk; Benita Middleton; Russell G Foster; Eileen M Joyce
Journal:  Br J Psychiatry       Date:  2011-12-22       Impact factor: 9.319

View more
  33 in total

1.  Actigraphy studies and clinical and biobehavioural correlates in schizophrenia: a systematic review.

Authors:  Zi Ying Wee; Samantha Wei Lee Yong; Qian Hui Chew; Cuntai Guan; Tih Shih Lee; Kang Sim
Journal:  J Neural Transm (Vienna)       Date:  2019-03-19       Impact factor: 3.575

2.  Adolescents at clinical-high risk for psychosis: Circadian rhythm disturbances predict worsened prognosis at 1-year follow-up.

Authors:  Jessica R Lunsford-Avery; Bruno da Silva Brandão Gonçalves; Elisa Brietzke; Rodrigo A Bressan; Ary Gadelha; Randy P Auerbach; Vijay A Mittal
Journal:  Schizophr Res       Date:  2017-02-04       Impact factor: 4.939

3.  Self-reported sleep disturbances associated with procedural learning impairment in adolescents at ultra-high risk for psychosis.

Authors:  Jessica R Lunsford-Avery; Derek J Dean; Vijay A Mittal
Journal:  Schizophr Res       Date:  2017-03-16       Impact factor: 4.939

4.  Dynamic endophenotypes and longitudinal trajectories: capturing changing aspects of development in early psychosis.

Authors:  Jai L Shah; M Mallar Chakravarty; Ridha Joober; Martin Lepage
Journal:  J Psychiatry Neurosci       Date:  2016-04       Impact factor: 6.186

5.  Sleeping Paranoia Away? An Actigraphy and Experience-Sampling Study with Adolescents.

Authors:  Timo Hennig; Tania M Lincoln
Journal:  Child Psychiatry Hum Dev       Date:  2018-02

6.  Sleep problems and attenuated psychotic symptoms in youth at clinical high-risk for psychosis.

Authors:  Katrina B Goines; Allison M LoPilato; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Daniel H Mathalon; Thomas H McGlashan; Diana O Perkins; Ming T Tsuang; Scott W Woods; Elaine F Walker
Journal:  Psychiatry Res       Date:  2019-08-03       Impact factor: 3.222

7.  Sleep disturbance and sleep-related impairment in psychotic disorders are related to both positive and negative symptoms.

Authors:  Jack J Blanchard; Alexandra Andrea; Ryan D Orth; Christina Savage; Melanie E Bennett
Journal:  Psychiatry Res       Date:  2020-02-07       Impact factor: 3.222

8.  Sleep Quality in Adolescents With Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME).

Authors:  Elisha K Josev; Melinda L Jackson; Bei Bei; John Trinder; Adrienne Harvey; Cathriona Clarke; Kelli Snodgrass; Adam Scheinberg; Sarah J Knight
Journal:  J Clin Sleep Med       Date:  2017-09-15       Impact factor: 4.062

9.  Sleep abnormalities in individuals at clinical high risk for psychosis.

Authors:  Ahmad Mayeli; Alice LaGoy; Francesco L Donati; Rachel E Kaskie; Seyed Morteza Najibi; Fabio Ferrarelli
Journal:  J Psychiatr Res       Date:  2021-03-08       Impact factor: 4.791

10.  Assessing the psychometric properties of the PROMIS sleep measures in persons with psychosis.

Authors:  Christina L G Savage; Ryan D Orth; Anyela M Jacome; Melanie E Bennett; Jack J Blanchard
Journal:  Sleep       Date:  2021-11-12       Impact factor: 6.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.